Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2500
Buy Report Download FREE Resources

Published: February 20, 2024 Report Code: GDHC7100CTIDB-ST

Select Item

HER2 Negative Breast Cancer Clinical Trial Analysis Report Overview

A total of 2,230 HER2- breast cancer clinical trials were conducted as of February 2024. The following are some of the key highlights of the HER2 breast cancer clinical trial report:

  • As of February 2024, North America led the HER2- breast cancer clinical trials landscape with more than 32% of the clinical trials conducted there.
  • In 2024, Pfizer conducted the highest number of HER2- breast cancer clinical trials.

The HER2- breast cancer clinical trial report provides a comprehensive understanding of the human epidermal growth factor receptor 2 negative breast cancer clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials.

Key Regions ·        North America

·        Europe

·        Asia-Pacific

·        Middle East and Africa

·        South and Central America
Key Countries ·        The US

·        Germany

·        The UK

·        Italy

·        Spain
Key Sponsor Types ·        Company

·        Institution

·        Government
Leading Sponsors ·        Pfizer Inc

·        Novartis AG

·        F. Hoffmann-La Roche Ltd

·        AstraZeneca Plc

·        Eli Lilly and Co
Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

HER2- Breast Cancer Clinical Trials Segmentation by Regions and Countries

The key regions considered for HER2- breast cancer clinical trials analysis are North America, Europe, Asia-Pacific, the Middle East and Africa, and South and Central America.

In the country-wise analysis, the US had the highest number of HER2- breast cancer clinical trials as of February 2024. Canada had the highest average patient enrollment in HER2- breast cancer clinical trials during the same time.

G7 countries: Among the G7 (United States, United Kingdom, Germany, France, Italy, Canada, and Japan) countries, France has the highest proportion of human epidermal growth factor receptor 2 negative breast cancer (HER2- breast cancer) in Oncology clinical trials as of February 2024.

E7 countries: Among the E7 (Brazil, Russia, India, China, Mexico, Turkey, and Indonesia) countries, Mexico has the highest proportion of human epidermal growth factor receptor 2 negative breast cancer (HER2- breast cancer) in Oncology clinical trials as of February 2024.

HER2- Breast Cancer Clinical Trials Analysis by Regions, 2024 (%)

HER2- Breast Cancer Clinical Trials Analysis by Regions, 2024 (%)

Buy the Full Report for More Regional Insights into the HER2- Breast Cancer Clinical Trials

Download a Free Sample Report

HER2- Breast Cancer Clinical Trials Segmentation by Sponsor Types

The key sponsor types for HER2- breast cancer clinical trials are company, institution, and the government. As of February 2024, the institution sponsor type conducted more than 49% of HER2- breast cancer clinical trials.

HER2- Breast Cancer Clinical Trials Analysis by Sponsor Types, 2024 (%)

HER2- Breast Cancer Clinical Trials Analysis by Sponsor Types, 2024 (%)

Buy the Full Report for More Sponsor Type Insights into the HER2- Breast Cancer Clinical Trials

Download a Free Sample Report

HER2- Breast Cancer Clinical Trials - Competitive Landscape

A few of the leading sponsors considered for HER2- breast cancer clinical trials analysis are:

  • Pfizer Inc
  • Novartis AG
  • Hoffmann-La Roche Ltd
  • AstraZeneca Plc
  • Eli Lilly and Co

HER2- Breast Cancer Clinical Trials Analysis by Sponsors, 2024 (%)

HER2- Breast Cancer Clinical Trials Analysis by Sponsors, 2024 (%)

Buy the Full Report to Know More about the Leading Sponsors of HER2- Breast Cancer Clinical Trials

Download a Free Sample Report

Segments Covered in the Report

HER2- Breast Cancer Clinical Trials Regional Outlook (2024)

  • North America
  • Europe
  • Asia-Pacific
  • Middle East and Africa
  • South and Central America

HER2- Breast Cancer Clinical Trials Country Outlook (2024)

  • The US
  • Germany
  • The UK
  • Italy
  • Spain

HER2- Breast Cancer Clinical Trials Sponsor Type Outlook (2024)

  • Company
  • Institution
  • Government

Scope

  • The report provides a snapshot of the global clinical trials landscape.

  • The report provides top-level data related to the clinical trials by region, country (G7 & E7), trial status, trial phase, sponsor type, and endpoint status.

  • The report reviews the top companies involved and enlists all trials (trial title, phase, and status) of the company.

  • The report provides all the unaccomplished trials (terminated, suspended, and withdrawn) with a reason for accomplishment.

  • The report provides enrollment trends for the past five years.

  • The report provides the latest news for the past three months.

Reasons to Buy

  • Formulate key business strategies for

  • Identify prominent locations for conducting clinical trials which saves time and cost.

  • Get top-level analysis of the Global Clinical Trials Market which helps in identifying key business opportunities.

  • Understand trial count and enrollment trends by country in the global therapeutics market.

  • Interpret the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended, or withdrawn) trials.

  • Understand clinical trial assessment of the indication on a global, regional, and country level.

Table of Contents

  • 1. Table of Contents

    • 1.1. List of Tables

    • 1.2. List of Figures

  • 2. Report Guidance

  • 3. GlobalData Clinical Trials Report Coverage

  • 4. Clinical Trials by Region

    • 4.1. Clinical Trials and Average Enrollment by Country

      • 4.1.1. Top Five Countries Contributing to Clinical Trials in Asia-Pacific

      • 4.1.2. Top Five Countries Contributing to Clinical Trials in Europe

      • 4.1.3. Top Countries Contributing to Clinical Trials in North America

      • 4.1.4. Top Five Countries Contributing to Clinical Trials in the Middle East and Africa

      • 4.1.5. Top Five Countries Contributing to Clinical Trials in Central and South America

  • 5. Clinical Trials by G7 Countries: Proportion of HER2- breast cancer to Oncology Clinical Trials

  • 6. Clinical Trials by Phase in G7 Countries

  • 7. Clinical Trials in G7 Countries by Trial Status

  • 8. Clinical Trials by E7 Countries: Proportion of HER2- breast cancer to Oncology Clinical Trials

  • 9. Clinical Trials by Phase in E7 Countries

  • 10. Clinical Trials in E7 Countries by Trial Status

  • 11. Clinical Trials by Phase

    • 11.1. In Progress Trials by Phase

  • 12. Clinical Trials by Trial Status

  • 13. Clinical Trials by End Point Status

  • 14. Subjects Recruited Over a Period of Time

  • 15. Clinical Trials by Sponsor Type

  • 16. Prominent Sponsors

    • 16.1. Top Companies Participating in HER2- breast cancer Therapeutics Clinical Trials

  • 17. Prominent Drugs

  • 18. Clinical Trial Profile Snapshots

  • 19. Appendix

    • 19.1. Abbreviations

    • 19.2. Definitions

    • 19.3. Research Methodology

    • 19.4. Secondary Research

    • 19.5. About GlobalData

    • 19.6. Contact Us

    • 19.7. Source

Table

Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics, Global, Clinical Trials by Region, 2024* 7_x000D_

Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2024* 9_x000D_

Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2024* 10_x000D_

Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2024* 11_x000D_

Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics Clinical Trials, Europe, Top Five Countries, 2024* 12_x000D_

Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics Clinical Trials, North America, Top Countries, 2024* 13_x000D_

Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2024* 14_x000D_

Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2024* 15_x000D_

Proportion of Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) to Oncology Clinical Trials, G7 Countries (%), 2024* 17_x000D_

Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics, G7 Countries, Clinical Trials by Phase, 2024* 19_x000D_

Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2024* 21_x000D_

Proportion of Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) to Oncology Clinical Trials, E7 Countries (%), 2024* 23_x000D_

Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics, E7 Countries, Clinical Trials by Phase, 2024* 25_x000D_

Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2024* 27_x000D_

Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics, Global, Clinical Trials by Phase, 2024* 28_x000D_

Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics, Global, Clinical Trials In Progress by Phase 2024* 29_x000D_

Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics, Global, Clinical Trials by Trial Status, 2024* 31_x000D_

Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics Clinical Trials, Global, by End Point Status, 2024* 32_x000D_

Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2019-2023 33_x000D_

Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2024* 34_x000D_

Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics Clinical Trials, Global, Key Sponsors, 2024* 36_x000D_

Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2024* 38_x000D_

Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2024* 40

Figures

Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics, Global, Clinical Trials by Region (%), 2024* 7_x000D_

Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2024* 8_x000D_

Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2024* 10_x000D_

Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2024* 11_x000D_

Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2024* 12_x000D_

Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics Clinical Trials, North America, Top Countries (%), 2024* 13_x000D_

Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2024* 14_x000D_

Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2024* 15_x000D_

Proportion of Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) to Oncology Clinical Trials, G7 Countries (%), 2024* 16_x000D_

Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics, G7 Countries, Clinical Trials by Phase, 2024* 18_x000D_

Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2024* 20_x000D_

Proportion of Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) to Oncology Clinical Trials, E7 Countries (%), 2024* 22_x000D_

Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics, E7 Countries, Clinical Trials by Phase, 2024* 24_x000D_

Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2024* 26_x000D_

Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics, Global, Clinical Trials by Phase (%), 2024* 28_x000D_

Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics, Global, Clinical Trials In Progress by Phase, 2024* 29_x000D_

Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics, Global, Clinical Trials by Trial Status, 2024* 30_x000D_

Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics Clinical Trials, Global, by End Point Status, 2024* 32_x000D_

Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2019-2023 33_x000D_

Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2024* 34_x000D_

Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics Clinical Trials, Global, Key Sponsors, 2024* 35_x000D_

Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2024* 37_x000D_

Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2024* 39_x000D_

GlobalData Methodology 1262

Frequently asked questions

Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update standard reports
Currency USD
$2,500

Can be used by individual purchaser only

Most Popular
$5,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) reports
Pharmaceuticals
New
Emerging Market Outsourcing Report, Q2 2026
$2,950 | July 2026
Pharmaceuticals
New
Focal Segmental Glomerulosclerosis (FSGS): Market View, Current and Future Competitive…
$3,495 | July 2026
Pharmaceuticals
New
Reflux Esophagitis (Gastroesophageal Reflux Disease): Market View, Current and Future…
$3,495 | June 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update in real time.

  • Access a live Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more